Background:
In conjunction with HIV antiretroviral treatment (ART) scale up, CD4 Point-of-Care (POC) assays are being utilized in resource-limiting settings to provide effective access to CD4 testing and determine eligibility for ART. Since 2009, the Alere Pima CD4 assay has been used for POC CD4 counts in resource-limiting setting and having an impact on HIV patient care. Many new POC CD4 assays are being introduced into the market, including the Zyomyx MyT4 and BD FACSPresto Near-Patient CD4 Counter. We assessed the quality, functionality, and performance of the MyT4 and FACSPresto assays in comparison with the established Pima CD4 assay.
Methods:
In 2014, we evaluated the MyT4 and FACSPresto assays. Whole blood specimens were analyzed for CD4 counts with the Pima CD4 and with the MyT4 (n=141) or FACSPresto (n=101). Scattered-plot and Bland-Altman analysis were done with Pima CD4 as the reference method. Precision of each assay was estimated by analyzing 3 specimens ten times on each platform and calculating the coefficient of variation (CV%). Error rates for each CD4 assay were assessed.
Results:
Scattered-plots and Bland-Altman analysis indicated that CD4 counts from both the MyT4 (R2=0.91, y=1.08x-28, bias +2 (-159, +156)) and FACSPresto (R2=0.96, y=1.15x+11, bias +78 (-59, +214)) correlated with the Pima CD4. CD4 counts with the MyT4 were estimated to have slightly more random error associated with the assay, while the FACSPresto CD4 counts were estimated to have a positive bias. Precision studies estimated the MyT4 to have a slightly higher CV% (8.2%) in comparison to FACSPresto (5.4%) and Pima (5.9%). Error rates increased on both MyT4 and FACSPresto with aged specimens (>12h, >20h), while the Pima CD4 was able to consistently analyze specimens up to 48 hours old.
Conclusions:
The Zyomyx MyT4 and BD FACSPresto correlated well with the Alere Pima CD4 and both prove to be acceptable methods for CD4 analysis. Both assays could potentially be used in point-of-care and resource-limiting settings.